

Document Type:	
71	
Safety Data Sheet	
Effective Date:	

03 DEC 2024

Propofol Injectable Emulsion, USP

SDS No.: **SDS019**

Revision No: **01**

Page **1 of 8**

Section 1 - Identification

(a) Product Identifier: Propofol Injectable Emulsion, USP (10 mg/mL)

(b) Product Code: 83634-603

Common/Trade Name: Diprivan

Chemical Name: 2,6 diisopropylphenol

Chemical Family: Anesthetic

(c) Product Use: Pharmaceutical, Injectable

Product Type: Regulated Prescription Drug

Container Information: Vial

(d) Distributor: Avenacy 10 N. Martingale Road, Suite 225, Schaumburg, IL

60173, 847-773-4901

(e) Emergency Telephone: 855-283-6229

Section 2 - Hazards Identification

(a) GHS Classification of substance or mixture:

Not classified.

(b) Signal Word, Hazard statement(s), Symbol(s), and/or Precautionary statement(s):	(c) Description of Hazards:
GHS Signal Word:	Not classified
GHS Hazard Statement:	Non-hazardous in accordance with international standards for workplace safety.
GHS Symbols:	Not classified
GHS Precautionary Statements:	Not classified
Other Hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).



Document Type: **Safety Data Sheet** Effective Date:

03 DEC 2024

Propofol Injectable Emulsion, USP

SDS No.: **SDS019** Revision No:

Page 2 of 8

Section 3 – Composition / Information on Ingredients

(a) Chemical Name	(b) Common Name / Synonym	% Composition or other measure	(c) CAS No.	(d) Impurities / Stabilizing Additives
2,6 diisopropylphenol	Propofol	10 mg/mL	2078-54-8	N/A
Soybean Oil	Soybean Oil	100 mg/mL	8001-22-7	NA
Glycerol	Glycerol	22.5 mg/mL	56-81-5	NA
Egg Phospholipid	Egg Phospholipid	12 mg/mL	93685-90-6	NA
Edetate Disodium	Edetate Disodium	0.055 mg/mL	6381-92-6	NA
Sodium Hydroxide	Sodium Hydroxide	q.s. for pH adjustment	1310-73-2	NA

Section 4 – First Aid Measures

Eye Exposure: Flush with water while holding eyelids open for at least 15 minutes. Seek

medical attention immediately.

Remove contaminated clothing. Flush area with large amounts of water. Use **Skin Exposure:**

soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth

with water. Do not induce vomiting unless directed by medical personnel.

Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention

immediately.

Injection: See patient package insert in shipping carton for complete information.

Notes to Physician: See patient package insert in shipping carton for complete information.

Section 5 – Fire-fighting Measures

Extinguishing (a) Use carbon dioxide, dry chemical, alcohol resistant-foam, or Media:

water spray.

Hazardous Formation of toxic gases is possible during heating or fire. **(b)**

Combustion **Products:**



Document Type:	
Safety Data Sheet	
Effective Date:	

03 DEC 2024

Propofol Injectable Emulsion, USP

SDS No.: SDS019 Revision No: **01**

Page **3 of 8**

(c) Special Protective Equipment /

Precautions:

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus and turnout gear.

Section 6 - Accidental Release Measures

Health and Safety Precautions:

Personnel involved in clean-up should wear appropriate personal

protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting:

Contain the source of spill if it is safe to do so. Clean spill area

thoroughly.

Measures for Environmental Protections:

Place waste in an appropriately labeled, sealed container for disposal.

Care should be taken to avoid environmental release.

Additional Considerations for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

Section 7 - Handling and Storage

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing.

Use appropriate personal protective equipment (PPE) while handling (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases

to the environment should be avoided.

Storage Conditions: Store as directed by product packaging.

Section 8 - Exposure Controls / Personal Protection

(a) Exposure Limits

Compound	Issuer	Type	Exposure Limit
Propofol	OSHA	PEL	NE
	ACGIH	TLV	NE
Soybean Oil	OSHA	PEL	NE
	ACGIH	TLV	NE
Glycerol	OSHA	PEL	15 mg/m³ (TWA)
	ACGIH	TLV	NE
Egg Phospholipid	OSHA	PEL	NE
	ACGIH	TLV	NE

(b) Engineering Controls

Engineering controls should be used as the primary means to control exposure. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.



Document Type:		
Safety Data Sheet		
Effective Date:		

03 DEC 2024

SDS No.:

SDS019

Propofol Injectable Emulsion, USP

Revision No: 01

Page **4 of 8**

(c) Individual Protection Measures

Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye Protection:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Skin Protection:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory Protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
Hand Protection:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent).

Section 9 - Physical and Chemical Properties

(a)	Appearance	Oily emulsion, white
(b)	Odor	None
(c)	Odor Threshold	Not available
(d)	рН	6.0 to 8.5
(e)	Melting Point:	Not determined
(f)	Initial Boiling Point:	242°C (468°F)
(g)	Flash Point (Liquid) (°C)	Not determined
(h)	Evaporation Rate:	Not determined
(i)	Flammability	Not determined
(j)	Upper Lower Flammability or Explosion Limits	Not determined
(k)	Vapor Pressure (kPa):	Not determined
(l)	Vapor Density:	Not determined
(m)	Relative Density	Not determined



Document Type: Safety Data Sheet	Propofol Injectable Emulsion, USP		
Effective Date: 03 DEC 2024	SDS No.:	Revision No: 01	Page 5 of 8

(n)	Solubility(ies)	Soluble in water
(0)	Partition Coefficient: n-octanol/water	Not available
(p)	Auto-ignition Temperature	Not available
(q)	Decomposition Temperature	Not available
(r)	Viscosity	Not available

Section 10 - Stability and Reactivity

(a)	Reactivity	Not determined
(b)	Chemical Stability	Stable under standard use and storage conditions.
(c)	Possibility of Hazardous Reactions	Not determined
(d)	Conditions to Avoid	Exposure to or contact with extreme temperatures, incompatible chemicals.
(e)	Incompatible Materials	As a precautionary measure, keep away from strong oxidizers.
(f)	Hazardous Decomposition Products	Formation of toxic gases is possible during heating or fire.

Section 11 - Toxicological Information

(a)	Likely Routes of Exposure	Skin, eyes, ingestion, inhalation
(b)	Symptoms related to the physical, chemical and toxicological characteristics	Clinical use of this drug has caused slow heart rate (bradycardia), decrease in blood pressure (hypotension), respiratory depression, skin rash, cough, drowsiness, sleepiness, dizziness, sedation, and gastrointestinal disturbance
(c)	Delayed and immediate effects and chronic effects from short and long term exposure	It is anticipated that for Occupational Exposure the target organs are: Acute: Skin, eyes, respiratory system. Chronic: None known from workplace exposure.

(d) Acute Toxicity:

Component	Type	Route	Species	Dosage
Propofol	LD_{50}	Dermal	Rabbit	>2,000 mg/kg
Propofol	LD ₅₀	Oral	Rat	500 mg/kg
Propofol	LD_{50}	Oral	Mouse	1,100 mg/kg



Document Type: Safety Data She	Propofol Injectable	Propofol Injectable Emulsion, USP	
Effective Date: 03 DEC 2024	SDS No.:	Revision No: 01	Page 6 of 8

Propofol	LD ₅₀	IV	Rat	42 mg/kg
Propofol	LD ₅₀	IV	Dog	30 mg/kg
Propofol	LD ₅₀	IV	Mouse	50 mg/kg
Propofol	LD ₅₀	Interperitoneal	Mouse	170 mg/kg

(e) Hazardous Chemical Listings: NTP: Not listed

IARC: Not listed OSHA: Not listed NIOSH: Not listed

Section 12 - Ecological Information

The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

(a)	Ecotoxicity	N/A
(b)	Persistence and degradability	N/A
(c)	Bioaccumulative potential	N/A
(d)	Mobility in soil	N/A
(e)	Other Adverse Effects	N/A

Section 13 - Disposal Considerations

Waste Disposal: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and waste water.

Section 14 - Transport Information

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15 - Regulatory Information

Below is selected regulatory information chosen primarily for possible Avenacy usage. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your country/state.

Propofol

SARA 313	Not Listed
Standard for the Uniform Scheduling for	Schedule 4

Drugs and Poisons (SUSMP)

EINECS List 218-206-6



Document Type: Safety Data Sheet	Propofol Injectable Emulsion, USP		
Effective Date: 03 DEC 2024	SDS No.: SDS019	Revision No: 01	Page 7 of 8

TSCA CERCLA AICS Present Not listed Present

Section 16 - Other Information

As of the date of effectiveness, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:

Avenacy 10 N. Martingale Road, Suite 225 Schaumburg, IL 60173 847-773-4901

Glossary: This glossary contains definitions of general terms used in SDSs. Not all of these Glossary Terms will apply to this SDS.

ACGIH	American Conference of Governmental Industrial Hygienists
AICS	Australian Inventory of Chemical Substances
AIHA	American Industrial Hygiene Association
ANSI	American National Standards Institute
CAS Number	Chemical Abstract Service Registry Number
CERCLA	Comprehensive Environmental Response Compensation and Liability Act (of
CHAN	Chemical Hazard Alert Notice
CHEMTREC	Chemical Transportation Emergency Center
DOT	Department of Transportation
DSL	Domestic Substances List
ECHA	European Chemicals Agency
EINECS	European Inventory of Existing Commercial Chemical Substances
ELINCS	European List of Notified Chemical Substances
EPA	Environmental Protection Agency
GHS	Globally Harmonized System of Classification and Labelling of Chemicals
HEPA	High Efficiency Particulate Air (Filter)
HMIS	Hazardous Materials Identification System
IARC	International Agency for Research on Cancer
ICAO/IATA	International Civil Aviation Organization/International Air Transport
IMO	International Maritime Organization
KOW	Octanol/Water Partition Coefficient
LEL	Lower Explosive Limit
MSDS	Material Safety Data Sheet
MSHA	Mine Safety and Health Administration



Document Type:
Safety Data Sheet
Effective Date:
03 DEC 2024

Propofol Injectable Emulsion, USP

SDS No.:
Revision No: Page 8 of 8

NA	Not Applicable, except in Section 14 where NA = North America
NE	Not Established
NADA	New Animal Drug Application
NAIF	No Applicable Information Found
NCI	National Cancer Institute
NDSL	Non-Domestic Substances List
NFPA	National Fire Protection Association
NIOSH	National Institute for Occupational Safety and Health
NPDES	National Pollutant Discharge Elimination System
NOS	Not Otherwise Specified
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
OEL	Occupational Exposure Limit
PEL	Permissible Exposure Limit (OSHA)
RCRA	Resource Conservation and Recovery Act
RQ	Reportable Quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SDS	Safety Data Sheet
STEL	Short Term Exposure Limit
TLV	Threshold Limit Value (ACGIH)
TPQ	Threshold Planning Quantity
TSCA	Toxic Substances Control Act
TWA	Time Weighted Average/8 Hours Unless Otherwise Noted
UEL	Upper Explosive Limit
UN	United Nations
USP	United States Pharmacopeia
WEEL	Workplace Environmental Exposure Level (AIHA)
WHMIS	Workplace Hazardous Materials Information System